PMID: 11929846Apr 4, 2002Paper

Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice

Human Molecular Genetics
Stewart A FabbG Dickson

Abstract

Duchenne muscular dystrophy is a severe life-threatening X-linked recessive disorder, caused by mutations in the dystrophin gene, for which currently there is no effective treatment. Because of the large size of the dystrophin cDNA (14 kb) this precluded it from being used in early adenovirus- or retrovirus-based gene therapy vectors. However, some therapeutic success has been achieved in mdx mice using adenovirus- and retrovirus-mediated transfer of a 6.3 kb recombinant mini-dystrophin cDNA. Despite this, problems with immunogenicity and inefficient transduction of mature myofibres make these vectors less than ideal for gene transfer to skeletal muscle. Adeno-associated viral (AAV) vectors overcome many of the problems associated with other vector systems. However, AAV vectors can only accommodate <5 kb of foreign DNA. For this reason we have produced a micro-dystrophin cDNA gene construct that is <3.8 kb. This construct, driven by a CMV promoter, was introduced into the skeletal muscle of 12-day-old nude/mdx mice using an AAV vector, resulting in specific sarcolemmal expression of micro-dystrophin in >50% of myofibres up to 20 weeks of age, and effective restoration of the dystrophin-associated protein (DAP) complex component...Continue Reading

Citations

Apr 14, 2006·Human Genetics·Kenneth H Warrington, Roland W Herzog
Nov 21, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Kathryn R Wagner
Jan 26, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mingju LiuDongsheng Duan
Jun 6, 2003·Current Opinion in Genetics & Development·Isin Dalkilic, Louis M Kunkel
Sep 11, 2002·Neuromuscular Disorders : NMD·Dominic J Wells, Kim E Wells
Sep 11, 2002·Neuromuscular Disorders : NMD·G DicksonS A Fabb
Sep 4, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Helen FosterGeorge Dickson
Mar 13, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Paul GregorevicJeffrey S Chamberlain
Jun 12, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Maëva Le HirStéphanie Lorain
Apr 19, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·DeWayne TownsendJoseph M Metzger
Aug 30, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Madoka IkemotoShin'ichi Takeda
Oct 12, 2010·The New England Journal of Medicine·Jerry R MendellChristopher M Walker
Feb 8, 2003·DNA and Cell Biology·Chooi May LaiP Elizabeth Rakoczy
Jun 1, 2012·Human Gene Therapy·Helen FosterGeorge Dickson
Jun 15, 2014·Neuromuscular Disorders : NMD·C Aaron Larsen, Michael T Howard
Feb 6, 2010·Expert Opinion on Biological Therapy·Ying TangBing Wang
Dec 7, 2011·The Journal of Gene Medicine·Taeyoung KooGeorge Dickson
Oct 27, 2006·Biochimica Et Biophysica Acta·Guy L OdomJeffrey S Chamberlain
Feb 25, 2015·Human Gene Therapy. Clinical Development·Dongsheng Duan
Sep 1, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Maria J MolnarGeorge Karpati
Aug 16, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Simone AbmayrJeffrey S Chamberlain
Oct 29, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Madoka YoshimuraShin'ichi Takeda
Aug 6, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·James E HagstromJon A Wolff
Sep 29, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Simon P QuennevilleJacques P Tremblay
Feb 24, 2006·Journal of Muscle Research and Cell Motility·Romesh A DraviamSimon C Watkins
Oct 4, 2003·Nature Reviews. Genetics·Judith C T van Deutekom, Gert-Jan B van Ommen
Feb 1, 2010·Viruses·Paul D WilliamsPaul A Kingston
Jul 29, 2006·Journal of Muscle Research and Cell Motility·Dominic J Wells
Aug 28, 2018·Annual Review of Pathology·Nazima ShahnoorMichael W Lawlor
Oct 17, 2008·Physiological Reviews·Jennifer DavisJoseph M Metzger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.